Survival according to TC class in relapsed and newly diagnosed patients. For this analysis, we grouped the maf and 4p16 classes (corresponding to poor prognosis genetic subtypes t(4;14) and t(14;16)) together, the D1 and D1 + D2 classes (corresponding mainly to hyperdiploid myeloma) together and the D2 + none classes together. (A) The survival of patients entered into single-agent bortezomib studies, calculated from day of commencing treatment to death, was presented as a Kaplan-Meier survival curve. Patients with 11q13 and 6p21 TC class (corresponding to t(11;14) and t(6;14), n = 29) had the worst prognosis compared with the maf and 4p16 group (n = 45), D1 and (D1 + D2) group (n = 78), and D2 + none group (n = 31) (median survival 13.1 months vs 15.6, 22.2, and 21.1 months, respectively; log-rank P = .036). On pair-wise comparison, only the survival of 11q13 was different from the other subtypes (log-rank P = .036). (B) For patients treated with total therapy II, survival was calculated from commencement of treatment until death. Patients in the 4p16 and maf group (n = 71) had the worst prognosis compared with 11q13 and 6p21 (n = 73), D1 and D1 + D2 (n = 141), and D2 + none group (n = 65) (median survival not reached for all at a median follow-up of 3.5 years; log-rank P = .02).